Anavex Life Sciences Corp (AVXL)

[stealthways]

IF 273 cures insomnia in AD patients then it follows that 273, as a minimum, should be either used in combo for all AD patients (since its safe and cures insomnia), or in conjunction with any other approved treatment, for the segment (40%) having insomnia.... So what I am saying is that if the data on insomnia is correct (100% correction of insomnia in AD) it follows that 273 should almost certainly get between 40% and 100% of the AD market penetration, in a worst case scenario (where it is found ineffective in a p3 trial to help AD....)
The above assumes 40% of patients of AD have insomnia.... and with this reasoning IMO... it looks like we know we have a winner, of at least 40% to 100% of the AD market...